



**HAL**  
open science

## Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)

Nathalie Ganne-Carrié, Richard Layese, Valérie Bourcier, Carole Cagnot, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Victor De De Lédighen, Denis Ouzan, et al.

### ► To cite this version:

Nathalie Ganne-Carrié, Richard Layese, Valérie Bourcier, Carole Cagnot, Patrick Marcellin, et al.. Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). *Hepatology*, 2016, 64 (4), pp.1136-1147. 10.1002/hep.28702. hal-01381662

**HAL Id: hal-01381662**

**<https://univ-rennes.hal.science/hal-01381662>**

Submitted on 26 Oct 2016

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Nomogram for individualized prediction of hepatocellular carcinoma occurrence in HCV-cirrhosis (ANRS CO12 CirVir)

**Short title:** Predictive score for HCC in HCV-cirrhosis.

Nathalie Ganne-Carrié<sup>1, 2, 3</sup>, MD ; Richard Layese<sup>4</sup>, Valérie Bourcier<sup>1</sup>, MD ; Carole Cagnot,<sup>5</sup> Patrick Marcellin<sup>6</sup>, MD; Dominique Guyader<sup>7</sup>, MD; Stanislas Pol<sup>8</sup>, MD; Dominique Larrey<sup>9</sup>, MD; Victor de Lédighen<sup>10</sup>, MD; Denis Ouzan<sup>11</sup>, MD; Fabien Zoulim<sup>12</sup>, MD; Dominique Roulot<sup>2, 13</sup>, MD; Albert Tran<sup>14</sup>, MD; Jean-Pierre Bronowicki<sup>15</sup>, MD; Jean-Pierre Zarski<sup>16</sup>, MD; Ghassan Riachi<sup>17</sup>, MD; Paul Calès<sup>18</sup>, MD; Jean-Marie Péron<sup>19</sup>, MD; Laurent Alric<sup>20</sup>, MD; Marc Bourlière<sup>21</sup>, MD; Philippe Mathurin<sup>22</sup>, MD; Jean-Frédéric Blanc<sup>23</sup>, MD; Armand Abergel<sup>24</sup>, MD; Lawrence Serfaty<sup>25</sup>, MD; Ariane Mallat<sup>26</sup>, MD; Jean-Didier Grangé<sup>27</sup>, MD; Pierre Attali<sup>28</sup>, MD; Yannick Bacq<sup>29</sup>, MD; Claire Wartelle<sup>30</sup>, MD; Thôn Dao<sup>31</sup>, MD; Yves Benhamou<sup>32</sup> MD; Christophe Pilette<sup>33</sup>, MD; Christine Silvain<sup>34</sup>, MD; Christos Christidis<sup>35</sup>, MD; Dominique Capron<sup>36</sup>, MD; Brigitte Bernard-Chabert<sup>37</sup>, MD; David Zucman<sup>38</sup>, MD; Vincent Di Martino<sup>39</sup>, MD; Jean-Claude Trinchet<sup>1, 2, 3</sup>, Pierre Nahon<sup>1, 2, 3</sup>, MD; Françoise Roudot-Thoraval<sup>4</sup>, MD and the ANRS CO12 CirVir study group.

<sup>1</sup>AP-HP, Hôpital Jean Verdier, Service d'Hépatologie, Bondy; <sup>2</sup>Université Paris 13, Sorbonne Paris Cité, "Equipe labellisée Ligue Contre le Cancer", F-93206 Saint-Denis; <sup>3</sup>Inserm, UMR-1162 "Génomique fonctionnelle des tumeurs solides", F-75010, Paris; <sup>4</sup>AP-HP, Hôpital Henri Mondor, Département de Santé Publique, Créteil; <sup>5</sup>Unit for Basic and Clinical research on Viral Hepatitis, ANRS (France REcherche Nord & Sud Sida-HIV Hépatites-FRENSH), <sup>6</sup>AP-HP, Hôpital Beaujon, Service d'Hépatologie, Clichy et université Paris 7; <sup>7</sup>CHU Pontchaillou, Service d'Hépatologie, Rennes; <sup>8</sup>Université Paris Descartes ; APHP, Unité d'Hépatologie, Hôpital Cochin ; INSERM U-818 et USM20, Institut Pasteur, Paris; <sup>9</sup>Hôpital Saint Eloi, Service d'Hépatologie, Montpellier; <sup>10</sup>Hôpital Haut-Lévêque, Service d'Hépatologie, Bordeaux; <sup>11</sup>Institut Arnaud Tzanck, Service d'Hépatologie, St Laurent du Var; <sup>12</sup>Hospices Civils de Lyon, Service d'Hépatologie, Université de Lyon, et INSERM U1052, Lyon; <sup>13</sup>AP-HP, Hôpital Avicenne, Service d'Hépatologie, Bobigny; <sup>14</sup>CHU de Nice, Service d'Hépatologie, F-06202, Cedex 3, Nice; Inserm U1065, C3M, Team 8, "Hepatic Complications in Obesity", F-06204, Cedex 3, Nice; <sup>15</sup>Inserm 954, CHU de Nancy, Université de Lorraine, Vandoeuvre-les-Nancy; <sup>16</sup>clinique d'hépto-gastroentérologie pôle Digidune Chu de Grenoble; <sup>17</sup>Hôpital Charles- Nicolle, Service d'Hépatologie. Rouen; <sup>18</sup>CHU d'Angers, Service d'Hépto-Gastroentérologie, et Université Bretagne-Loire; <sup>19</sup>Hôpital Purpan, Service d'Hépatologie, et université Paul Sabatier III, Toulouse; <sup>20</sup>CHU Toulouse, Service de Médecine Interne-Pôle Digestif UMR 152, Toulouse; <sup>21</sup>Hôpital Saint Joseph, Service d'Hépatologie, Marseille; <sup>22</sup>Hôpital Claude Huriez, Service d'Hépatologie, Lille; <sup>23</sup>Hôpital St André, Service d'Hépatologie, Bordeaux; <sup>24</sup>Hôpital Hôtel Dieu, Service d'Hépatologie, Clermont-Ferrand; <sup>25</sup>AP-HP, Hôpital Saint- Antoine, Service d'Hépatologie, Paris; <sup>26</sup>AP-HP, Hôpital Henri Mondor, Service d'Hépatologie, Créteil; <sup>27</sup>AP-HP, Hôpital Tenon, Service d'Hépatologie, Paris; <sup>28</sup>AP-HP, Hôpital Paul Brousse, Service d'Hépatologie, Villejuif; <sup>29</sup>Hôpital Trousseau, Unité d'Hépatologie, CHRU de Tours; <sup>30</sup>Hôpital d'Aix-En-Provence, Service d'Hépatologie, Aix-En-Provence; <sup>31</sup>Hôpital de la Côte de Nacre, Service d'Hépatologie, Caen; <sup>32</sup>AP-HP, Groupe Hospitalier de La Pitié-Salpêtrière, Service d'Hépatologie, Paris; <sup>33</sup>CH Le Mans, Service d'Hépatologie, Le Mans; <sup>34</sup>CHU de Poitiers, Service d'Hépatologie, Poitiers; <sup>35</sup>Institut Mutualiste Montsouris, Service d'Hépatologie, Paris; <sup>36</sup>Hôpital Amiens Nord, Service d'Hépatologie, Amiens; <sup>37</sup>Hôpital Robert Debré, Service d'Hépatologie, Reims; <sup>38</sup>Hôpital Foch, Service de Médecine Interne, Suresnes; <sup>39</sup>Hôpital Jean Minjot, Service d'Hépatologie, Besançon, FRANCE.

**Author contributions:** Professors Ganne-Carrié and Dr. Roudot-Thoraval had full access to all data in the study and take responsibility for the integrity of data and the accuracy of data analysis. Dr. Nahon has listed everyone who contributed significantly to this work.

**Study concept and design:** Prof. Ganne-Carrié, Dr. Nahon, Dr. Bourcier, Dr. Roudot-Thoraval.

**Acquisition of data:** Prof. Ganne-Carrié, Dr. Bourcier, Mr. Layese, Prof. Marcellin, Prof. Guyader, Prof. Pol, Prof. Larrey, Prof. De Lédighen, Dr. Ouzan, Prof. Zoulim, Prof. Roulot, Prof. Tran, Prof. Bronowicki, Prof. Zarski, Dr. Riachi, Prof. Calès, Prof. Péron, Prof. Alric, Dr. Bourlière, Prof. Mathurin, Prof. Blanc, Prof. Abergel, Dr. Serfaty, Prof. Mallat, Dr. Grangé, Dr. Attali, Dr. Bacq, Dr.

Wartelle, Prof. Dao, Dr. Benhamou, Dr. Pilette, Prof. Silvain, Dr. Christidis, Prof. Capron, Dr. Bernard-Chabert, Dr. Zucman, Prof. Di Martino, Dr. Nahon, Dr. Roudot-Thoraval.

**Analysis and interpretation of data:** Prof. Ganne-Carrié, Dr. Bourcier, Mr. Layese, Dr. Nahon, Dr. Roudot-Thoraval.

**Drafting of the manuscript:** Prof. Ganne-Carrié, Dr. Bourcier, Mr. Layese, Dr. Nahon, Dr. Roudot-Thoraval.

**Critical revision of the manuscript for important intellectual content:** Prof. Ganne-Carrié, Dr. Bourcier, Mr. Layese, Dr. Nahon, Dr. Roudot-Thoraval.

**Statistical analysis:** Mr Layese, Dr. Roudot-Thoraval

**Obtained funding:** Pr. Trinchet

**Administrative, technical and material support:** Dr. Nahon, Dr. Bourcier, Mrs. Cagnot, Mr. Layese, Dr. Roudot-Thoraval.

**Study supervision:** Prof. Ganne-Carrié, Dr. Bourcier, Mr. Layese, Dr. Nahon, Dr. Roudot-Thoraval.

**Funding/Support:** This study was sponsored by the ANRS (France REcherche Nord & Sud Sida-hiv Hépatites: FRENH).

**Role of the sponsor:** The funding sponsor had no role in the design or conducting of the study: collection, management, analysis, interpretation of data, nor preparation, review or approval of the manuscript.

#### ANRS CO12 CirVir group:

Pierre Nahon<sup>1</sup>, Patrick Marcellin<sup>2</sup>, Dominique Guyader<sup>3</sup>, Stanislas Pol<sup>4</sup>, Hélène Fontaine<sup>4</sup>, Dominique Larrey<sup>5</sup>, Victor De Lédighen<sup>6</sup>, Denis Ouzan<sup>7</sup>, Fabien Zoulim<sup>8</sup>, Dominique Roulot<sup>9</sup>, Albert Tran<sup>10</sup>, Jean-Pierre Bronowicki<sup>11</sup>, Jean-Pierre Zarski<sup>12</sup>, Vincent Leroy<sup>12</sup>, Ghassan Riachi<sup>13</sup>, Paul Calès<sup>14</sup>, Jean-Marie Péron<sup>15</sup>, Laurent Alric<sup>16</sup>, Marc Bourlière<sup>17</sup>, Philippe Mathurin<sup>18</sup>, Sebastien Dharancy<sup>18</sup>, Jean-Frédéric Blanc<sup>19</sup>, Armand Abergel<sup>20</sup>, Lawrence Serfaty<sup>21</sup>, Ariane Mallat<sup>22</sup>, Jean-Didier Grangé<sup>23</sup>, Pierre Attali<sup>24</sup>, Yannick Bacq<sup>25</sup>, Claire Wartelle<sup>26</sup>, Thông Dao<sup>27</sup>, Yves Benhamou<sup>28</sup>, Christophe Pilette<sup>29</sup>, Christine Silvain<sup>30</sup>, Christos Christidis<sup>31</sup>, Dominique Capron<sup>32</sup>, Gérard Thieffin<sup>33</sup>, Sophie Hillaire<sup>34</sup>, Vincent Di Martino<sup>35</sup>.

<sup>1</sup>AP-HP, Hôpital Jean Verdier, Service d'Hépatologie, Bondy, Université Paris 13, Bobigny et INSERM U1162, Université Paris 5, Paris; <sup>2</sup>AP-HP, Hôpital Beaujon, Service d'Hépatologie, Clichy; <sup>3</sup>CHU Pontchaillou, Service d'Hépatologie, Rennes; <sup>4</sup>AP-HP, Hôpital Cochin, Département d'Hépatologie et INSERM UMS20, Institut Pasteur, Université Paris Descartes, Paris; <sup>5</sup>Hôpital Saint Eloi, Service d'Hépatologie, Montpellier; <sup>6</sup>Hôpital Haut-Lévêque, Service d'Hépatologie, Bordeaux; <sup>7</sup>Institut Arnaud Tzanck, Service d'Hépatologie, St Laurent du Var; <sup>8</sup>Hôpital Hôtel Dieu, Service d'Hépatologie, Lyon; <sup>9</sup>AP-HP, Hôpital Avicenne, Service d'Hépatologie, Bobigny; <sup>10</sup>CHU de Nice, Service d'Hépatologie, et INSERM U1065, Université de Nice-Sophia-Antipolis, Nice; <sup>11</sup>Hôpital Brabois, Service d'Hépatologie, Vandoeuvre-les-Nancy; <sup>12</sup>Hôpital Michallon, Service d'Hépatologie, Grenoble; <sup>13</sup>Hôpital Charles-Nicolle, Service d'Hépatologie, Rouen; <sup>14</sup>CHU d'Angers, Service d'Hépatologie, Angers; <sup>15</sup>Hôpital Purpan, Service d'Hépatologie, Toulouse; <sup>16</sup>CHU Toulouse, Service de Médecine Interne-Pôle Digestif UMR 152, Toulouse; <sup>17</sup>Hôpital Saint Joseph, Service d'Hépatologie, Marseille; <sup>18</sup>Hôpital Claude Huriez, Service d'Hépatologie, Lille; <sup>19</sup>Hôpital St André, Service d'Hépatologie, Bordeaux; <sup>20</sup>Hôpital Hôtel Dieu, Service d'Hépatologie, Clermont-Ferrand; <sup>21</sup>AP-HP, Hôpital Saint-Antoine, Service d'Hépatologie, Paris; <sup>22</sup>AP-HP, Hôpital Henri Mondor, Service d'Hépatologie, Créteil; <sup>23</sup>AP-HP, Hôpital Tenon, Service d'Hépatologie, Paris; <sup>24</sup>AP-HP, Hôpital Paul Brousse, Service d'Hépatologie, Villejuif; <sup>25</sup>Hôpital Trousseau, Unité d'Hépatologie, CHRU de Tours; <sup>26</sup>Hôpital d'Aix-En-Provence, Service d'Hépatologie, Aix-En-Provence; <sup>27</sup>Hôpital de la Côte de Nacre, Service d'Hépatologie, Caen; <sup>28</sup>AP-HP, Groupe Hospitalier de La Pitié-Salpêtrière, Service d'Hépatologie, Paris; <sup>29</sup>CHU Le Mans, Service d'Hépatologie, Le Mans; <sup>30</sup>CHU de Poitiers, Service d'Hépatologie, Poitiers; <sup>31</sup>Institut Mutualiste Montsouris, Service d'Hépatologie, Paris; <sup>32</sup>Hôpital Amiens Nord, Service d'Hépatologie, Amiens; <sup>33</sup>Hôpital Robert Debré, Service

d'Hépatologie, Reims; <sup>34</sup>Hôpital Foch, Service d'Hépatologie, Suresnes; <sup>35</sup>Hôpital Jean Minjot, Service d'Hépatologie, Besançon. FRANCE.

**Declaration of interests:** Prof. Ganne-Carrié and Dr. Nahon received honoraria from Bayer, Bristol-Myers Squibb, and Gilead. Prof. Zarski consults for and is on the speakers' bureau of Gilead, Bristol-Myers Squibb, Janssen, Siemens and MSD. He consults for AbbVie. Prof. Pol was a speaker for GSK, BMS, Boehringer Ingelheim, Janssen Gilead, Roche, MSD, Sanofi, Novartis, Vertex and Abbvie. He received grants from Bristol-Myers Squibb, Gilead, Roche, and MSD. He consults for Gilead, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, Vertex, Janssen, AbbVie, Sanofi, Novartis and GlaxoSmithKline. Prof. Alric consults for and received grants from Bristol-Myers Squibb, MSD, and Gilead. He received grants from Roche and Janssen. Dr. Bourliere consults for and advises AbbVie, MSD, Janssen, Bristol-Myers Squibb, Roche and Gilead. Prof. Di Martino consults for and advises Gilead, MSD, Janssen and Bristol-Myers Squibb. Dr. Bacq has served as a speaker for Roche, Gilead or Bristol-Myers Squibb. Dr Roudot-Thoraval is an advisor for Roche, Gilead and AbbVie, and served as speaker for Roche, Bristol-Myers Squibb, AbbVie, Gilead.

**Correspondence:** Nathalie Ganne-Carrié, MD, PhD Email: [nathalie.ganne@jvr.aphp.fr](mailto:nathalie.ganne@jvr.aphp.fr)

**Acknowledgements:** This work is dedicated to the memory of Prof. Jean-Claude Trinchet.

**Electronic word counts:** *Title:* 113 /120; *Abstract:* 255/ 275 *Manuscript (pages 4 to 18):* 5521/ 6000;

**Figures:** 3; **Tables:** 4

**Abbreviations:** HBV: hepatitis B virus; HCV: hepatitis C virus; HCC: hepatocellular carcinoma; AFP: alfa-fetoprotein; SVR: sustained virological response.

**ABSTRACT**

*Background:* To develop an individualized score for predicting hepatocellular carcinoma (HCC) in patients with hepatitis C (HCV)-compensated cirrhosis.

*Methods:* Among 1,323 patients with HCV-cirrhosis enrolled in the French prospective ANRS CO12 CirVir cohort, 720 and 360 were randomly assigned to training and validation sets, respectively. Cox multivariate model was used to predict HCC, after which a nomogram was computed to assess individualized risk.

*Results:* During follow-up (median: 51.0 months), 103 and 39 patients developed HCC in the training and validation sets, respectively. Five variables were independently associated with occurrence of HCC: age > 50 years (HR 1.94, 95%CI [1.16; 3.25], p=0.012); past excessive alcohol intake (HR 1.55, 95%CI [1.02; 2.36], p=0.041); low platelet count (< 100 Giga/ mm<sup>3</sup>: HR 2.70, 95% CI [1.62; 4.51], p < 0.001; [100; 150] Giga/ mm<sup>3</sup>: HR 1.87, 95%CI [1.10; 3.18], p=0.021); GGT above the upper limit of normal (HR 1.96, 95%CI [1.11; 3.47], p=0.021); and absence of a sustained virological response during follow-up (HR 3.02, 95%CI [1.67; 5.48], p<0.001). An 11-point risk score was derived from the training cohort and validated in the validation set. Based on this score, the population was stratified into three groups, in which HCC development gradually increased, from 0% to 30.1% % at 5 years for patients with the lowest ( $\leq 3$ ) and highest ( $\geq 8$ ) scores (p < 0.001). Using this score, a nomogram was built enabling individualized prediction of HCC occurrence at 1, 3 and 5 years.

*Conclusions:* This HCC score can accurately predict HCC at an individual level in French patients with HCV-cirrhosis.

Approximately 80% of hepatocellular carcinomas (HCC) worldwide are related to chronic infection with hepatitis B (HBV) or hepatitis C virus (HCV).

In Western countries, spread of HCV infection has been partly responsible for a rise in the incidence of cirrhosis and HCC during recent decades (1). In those countries, historical cohort studies reported 5-year cumulative incidences of HCC of nearly 17% in patients with HCV-cirrhosis (2). More recently, large prospective Western cohorts confirmed the high incidence of HCC in HCV-cirrhosis: in the subgroup of 410 patients with HCV-cirrhosis enrolled in the HALT-C American cohort, and who did not respond to peg-interferon and ribavirin (3), and among 1,323 patients with histologically proven and uncomplicated HCV cirrhosis enrolled from 2006 to 2012 in the ANRS CO12 CirVir French multicenter cohort (4), cumulative HCC incidences were 7% at 5 years and 11.4% at 4 years, respectively. Since HCC screening is considered cost-effective if the incidence of HCC is over 1.5% per year (5, 6), patients with HCV-cirrhosis should thus undergo periodic surveillance for HCC. Moreover, in the ANRS CO12Cirvir French prospective cohort, this policy of periodic surveillance of cirrhosis was successful and resulted in detection of a high proportion of small HCC, fulfilling Milan criteria in 80% of cases and enabling curative treatment in 70% of cases (4).

However, while patients with cirrhosis, whatever its etiology, are at risk of HCC and should undergo periodic surveillance, experience shows that not all of them have the same risk of developing HCC, suggesting that HCC surveillance in certain subsets of cirrhotic patients may not be cost-effective. Several potential factors have been shown to be independently associated with higher risk of HCC occurrence in patients with HCV-cirrhosis: a) host factors, including male gender (7, 8), increasing age (3, 7, 8), black origins (3), diabetes and overweight (8); b) virological factors such as detectable serum HCV RNA (9) and HCV genotypes 1 (4) or 3 (10); c) disease factors, including liver failure assessed by albumin serum level (4) and portal hypertension assessed either by low platelet count (4) or by esophageal varices (3, 7); and d) environmental factors such as tobacco intake. Conversely, other factors were identified with lower risk of HCC and might be chemoprotective in patients with HCV-cirrhosis, such as coffee consumption (11) and metformin (12) or statin treatment (13).

However, at an individual level, it remains difficult to assess the specific risk of HCC in a patient with HCV-cirrhosis, or to advise that person on the need for periodic screening for HCC. Personalized assessment of individual risk of HCC thus represents a challenge.

Therefore, the aims of this study were to build and validate a simple personalized scoring system using baseline independent variables for HCC occurrence, and to develop a nomogram for predicting HCC risk in patients with HCV-related compensated cirrhosis included in the large French prospective multicenter ANRS CO12 CirVir cohort (4).

## **METHODS**

### ***Patient selection***

Among patients with biopsy-proven compensated (Child-Pugh A) and uncomplicated virus-related cirrhosis who were enrolled in the French multicenter ANRS CO12 CirVir cohort between March 2006 and July 2012 and prospectively followed up for development of HCC (4), those with chronic infection by HCV (positive HCV serology whatever the level of viral replication) and without HBV co-infection (negative serum HBsAg) were selected. If data on well known predictive factors for HCC occurrence in patients with cirrhosis were not available, patients were secondarily excluded.

Pre-inclusion assessment included usual clinical and biological parameters (gender, age, body mass index (BMI), diabetes, arterial hypertension, dyslipidemia, metabolic syndrome, prothrombin time, bilirubin serum level, albumin serum level, platelet count, liver enzymes (ASAT, ALAT, GGT), AFP serum level, esophageal varices, HCV genotype, HCV viral load, HIV co-infection), histological lesions of steato-hepatitis and a Doppler ultrasonography (US) to rule out complications at baseline, including HCC.

Patient information was recorded in a computerized database by a clinical research associate specifically dedicated to the ANRS CO12 CirVir cohort at each center. For all patients, past and ongoing alcohol or tobacco consumption was quantified and recorded at inclusion.

Excessive alcohol consumption was defined according to World Health Organization criteria (more than 2 glasses per day for females and more than 3 glasses per day for males); an overall minimal duration of 5 years was required.

Past medical history was also noted. In particular, the senior hepatologist in charge of a given patient at each center determined whether metabolic syndrome was present or not, based on clinical guidelines (14) and/or histological examination of liver biopsy (15).

***Follow-up***

Follow-up was scheduled according to French guidelines (Haute Autorité de Santé). Examination by Doppler US was performed every 6 months. For a given patient, it was recommended that US be formed at the same center by an experienced operator. A report was completed by each operator, mentioning the presence or not of focal liver lesions.

All events occurring during follow-up, liver-related or not, were recorded based on information obtained from medical files of patients at each center, and monitored by a panel of 3 dedicated clinical research associates. All treatments, including antiviral therapy, were recorded at inclusion, and any modification during follow-up was notified.

***HCC diagnosis and treatment***

In case of focal liver lesions detected by US, the following procedures were carried out: i) echogenicity, number and diameter of nodules (classified as <10 mm, 11-20 mm, 21-30 mm, 31-50 mm or >50 mm) and anatomic localization according to the Couinaud classification were reported; ii) portal vasculature (main trunk and branches), hepatic veins, and vena cava were systematically examined; and iii) a diagnostic procedure using contrast-enhanced imaging (CT-scan or MRI), serum alpha-fetoprotein (AFP) assay and/or guided biopsy was performed according to 2005 AASLD guidelines (6) updated in 2011 (16). HCC diagnosis was thus established either by histological examination by an experienced pathologist, or using probabilistic non-invasive criteria (mainly dynamic imaging showing early arterial hypervascularization and portal washout) according to the different periods of time (before and after 2011). When the HCC diagnosis was established, treatment was decided using a multidisciplinary approach according to AASLD or EASL guidelines for HCC (5, 6, 16). Reports of imaging techniques showing liver focal lesions were secondarily reviewed by the two senior hepatologists from institution 1 (authors VB and PN).

***Antiviral treatment and viral replication***

From 2006 to January 2014 (before the introduction of second-generation direct antiviral agents [DAAs] in France), all antiviral therapies conducted were interferon-based according to international guidelines. Since January 2014, patients could also receive second-generation DAAs with or without pegylated interferon and ribavirin for 12 to 24 weeks as part of early access programs, or after market approval according to national and/or international guidelines. The primary efficacy outcome was a SVR, defined as HCV RNA undetectable by qualitative polymerase chain reaction assay ( $< 50$  IU/mL) at the end of either a 24-week untreated follow-up period for interferon-based antiviral therapies without second generation DAAs, or a 12-week untreated follow-up period for antiviral therapy, including second generation DAAs.

### *Statistical analyses*

To internally validate the final adjusted HCC algorithm, we used a split-sample approach to assess discrimination, calibration and predictive ability of the model. We randomly divided the studied population of HCV-related Child-Pugh A cirrhosis into a development subset (2/3, on which model parameter estimates and the corresponding model-based HCC probabilities were derived) and a validation subset (1/3) to which model results were applied), and used our final model in these 2 samples.

Descriptive statistics are presented for the entire cohort and for the 2 subsets, as median [interquartile range (IQR)] for continuous variables and as numbers (percentages) for categorical data. Comparisons of patient subsets were performed using the Student t-test or Wilcoxon rank sum test for continuous variables, and the Chi-square or Fisher's exact test for categorical variables.

The cumulative incidence of HCC was estimated in the training cohort in a competing risks framework, where deaths free of HCC were considered as competing events. Since no difference was observed with Kaplan-Meier estimates, univariate and multivariate Cox proportional hazards models were used in the training cohort to assess factors associated with occurrence of HCC. In particular, the effect of a SVR was assessed in Cox regression as a time-dependent co-variate, since patients without SVR at inclusion could be (re)treated and achieve SVR during follow-up. For these patients, end of treatment was defined as time T0, since patients with undetectable HCV RNA at that time were

considered as having a SVR. All variables tested in univariate Cox analysis with a p value less than 0.20 were tested in multivariate Cox regression.

A predictive score was then constructed as a weighted sum of all independent predictive factors for the occurrence of HCC, identified in Cox multivariate analysis. The weight of each factor was given by a linear transformation (multiplied by 3) of the estimated coefficient in Cox regression analysis and rounded off to the nearest integer. Baseline HCC-free probabilities were also estimated from Cox multivariate analysis at 1, 3 and 5 years. Predicted risks for HCC were estimated by the following equation:  $1 - P_0^{\exp(\sum \tilde{\beta} \times score)}$ , where  $P_0$  was baseline HCC-free probability and  $\tilde{\beta} = \frac{1}{3}$  was the inverse multiplicative coefficient used to build the HCC score. Predicted probabilities of HCC at 1, 3 and 5 years are presented for each level of the score as a nomogram.

Cumulative incidence curves according to the different risk groups of HCC determined from the score were built using a clock reset approach. Patients who switched from non-SVR to SVR status were censored at the time of SVR, which was the date of the end of treatment. The time of SVR was reset at time 0 for patients having SVR status during follow-up.

Comparison of cumulative incidence curves was assessed with univariate Cox regression analyses.

Discrimination was assessed by receiver operating curve (ROC) analysis. Overall predictive accuracy of the derived score for predicting the development of HCC at 1 and 3 years after inclusion was tested by estimating the area under the ROC curve (AUROC).

Calibration of the model was assessed by Harrell's C statistics and the correlation coefficient between predicted and observed probabilities of HCC.

The score was secondarily tested in the validation cohort.

Lastly, the score was reassessed after twelve months of follow-up.

All statistical analyses were performed using Stata 13.0 (StataCorp, College Station, TX). A *P* value of 0.05 or less was considered statistically significant.

## **RESULTS**

## HEP-16-0255

Among 1,671 patients consecutively enrolled between March 2006 and July 2012 in the French ANRS CO12 CirVir cohort, 1,323 patients had HCV-cirrhosis and were HBsAg-seronegative. Secondly, 243 of them were excluded from analysis due to missing data regarding known predictive factors for HCC. Finally, 1,080 patients were analyzed and randomly assigned to training (n=720) and validation (n=360) sets (Figure 1).

Patient characteristics at inclusion were similar in the two groups, except for prothrombin time, which was slightly higher in the validation group. Patients were mainly male (64.0%), median age 55.6 years [48.9-64.0]. Median body mass index was 25.7 kg/m<sup>2</sup>. Co-morbidities were frequent, including overweight or obesity in 57.8%, diabetes in 18.9% and past excessive alcohol consumption in 31.3% of cases (median alcohol consumption 80 g/day (IQR 50-100) for 11.5 years (IQR 10-20)). Patients were mainly mono-infected (4.6% of patients with HIV co-infection) by genotype 1 (69.1%). Only 212 (19.6%) of them had SVR at baseline, confirmed at endpoint; overall, at endpoint, 427 of the 1,080 selected patients (39.5%) had SVR, including 215 who achieved SVR during follow-up (Table 1).

During a median follow-up of 51.0 months [32.3-71.9], a diagnosis of HCC was established for 142 of the 1,080 selected patients, i.e. 103 and 39 in the training and validation sets, respectively (Figure 1; Table 2).

Most HCCs were uni-nodular (n=87, 64.9%) and smaller than 30 mm (n=100, 80.0%). Portal obstruction and a serum AFP level >200 ng/mL at diagnosis were observed in 7.9% and 12.3%, respectively. Overall, 107 (75%) patients with HCC fell within Milan criteria, and curative treatment as first-line therapy was performed in 83 (66.4%). There were no significant differences in HCC characteristics between the two groups of patients (Table 2).

### Training cohort

Based on multivariate Cox regression analysis, 5 out of 23 variables listed in Table 3 were independently associated with occurrence of HCC in the training cohort: age > 50 years (HR 1.94, 95% CI [1.16; 3.25], p=0.012); past excessive alcohol intake (HR 1.55, 95% CI [1.02; 2.36], p=0.041); low platelet count (< 100 Giga/mm<sup>3</sup>: HR 2.70, 95% CI [1.62; 4.51], p < 0.001; [100; 150] Giga/mm<sup>3</sup>): HR 1.87, 95% CI [1.10; 3.18], p=0.021); GGT above the upper limit of normal (ULN): HR

## HEP-16-0255

1.96, 95% CI [1.11; 3.47],  $p=0.021$ ); and no occurrence of SVR during the study period: HR 3.02, 95% CI [1.67; 5.48],  $p<0.001$ ) (Table 3). An 11-point risk score was derived from the estimated  $\beta$ -regression coefficients of these 5 variables, by linear transformation (multiplied by 3) of the coefficients and rounding off (Table 4). The population was stratified into three groups according to this scoring system, with HCC occurrence gradually increasing from 2% to 30.1% at 5 years for patients with the lowest ( $\leq 3$ ,  $n = 117$ , 13.8%) and highest ( $\geq 8$ ,  $n = 349$ , 40.6%) HCC risk scores, respectively ( $p < 0.001$ , Figure 2A). AUROC for 1- and 3-year predictions after baseline was 0.678 [0.555-0.801] and 0.717 [0.661-0.773], respectively, in the training group. Implementation of this score after twelve months of follow-up, taking into account increasing age, new values of platelets and GGT and potential recent SVR, gave an AUROC for the 1 and 3-year predictions of 0.678 [0.574-0.783] and 0.727 [0.655- 0.800], respectively, in this subset of patients still at risk of HCC.

In order to develop an individualized prediction of HCC, a nomogram derived from this score was also built, given the 1-, 3-, and 5-year probabilities of HCC for each level of the score (Figure 3). The fit of the model was assessed by Harrell's C statistics at 0.72.

Calibration was also assessed for predicted HCC risk and observed risk, and showed a good correlation ( $r=0.91$ ,  $p<0.001$ ).

### Validation set

The cumulative incidence of HCC risk was estimated by the Kaplan-Meier method according to the 3 groups of the score built from the training cohort. HCC occurrence gradually increased from 0% to 20.3% at 5 years, for patients with the lowest ( $\leq 3$ ,  $n = 64$ , 14.7%) and highest ( $\geq 8$ ,  $n = 165$ , 37.9%) HCC risk scores ( $p < 0.001$ , Figure 2B).

In this group, the AUROC for the 3-year prediction of HCC was 0.736 [0.639-0.833], similar to that of the training group ( $p=0.75$  between AUCs). Correlation between observed and predicted HCC risk was estimated with a coefficient at 0.86 ( $p<0.001$ )

## DISCUSSION

Our results show that personalized prediction of HCC using easily available variables is feasible in

patients with HCV-related cirrhosis. Indeed, a simple score combining 4 baseline variables and 1 time-dependent variable was accurate in predicting HCC at the individual level in a large prospective cohort of French patients with HCV-cirrhosis. Relevant baseline independent variables used in this score were in accordance with the literature; indeed, increasing age (3, 7, 8), low platelet counts (4) and detectable serum HCV RNA (9) are the usual predictive factors for occurrence of HCC in patients with cirrhosis.

Conversely, it takes in account an original variable - the serum level of GGT - that was less frequently reported as an independent predictive factor for HCC (17-19) and not previously used by another scoring system. This simple test mainly summarizes the weight of co-morbidities, as patients with GGT above ULN (76%) had a higher body mass index (25.9 [23.1 – 29.1] vs 25.4 [22.7 – 28.1],  $p = 0.038$ ), more frequent dyslipidemia (6% vs 3.2%,  $p = 0.042$ ) and more frequent histological evidence of steato-hepatitis (44.8% versus 25.5 %,  $p = 0.01$ ). Conversely, patients with GGT above the upper limit of normal did not have an increased proportion of diabetes (20.1% vs 16.4%,  $p = 0.13$ ), suggesting that increased serum GGT could be a very early surrogate marker of insulin resistance. Furthermore, an increased serum level GGT ( $> ULN$ ) is usually associated with more severe liver disease.

This model, which can be easily applied to clinical practice, performed well in terms of discrimination (AUROC for 1- and 3-year predictions was 0.678 [0.555-0.801] and 0.717 [0.661-0.773], respectively, in the training group) in a split derivation sample of patients with HCV-related cirrhosis. Internal validation in the split sample confirmed the accuracy of this score in predicting HCC; the derived nomogram had good calibration, with an accurate correlation between predicted and observed HCC risk ( $r = 0.91$ ). Moreover, updating of the score value 12 months after inclusion for patients still at risk of HCC was able to predict, with the same discriminatory accuracy, the risk of HCC, demonstrating the evolutive capacity of the score.

Numerous personalized risk-scoring systems constructed using baseline-independent variables for HCC occurrence had been previously developed and validated in patients with cirrhosis due to various causes (8, 20, 21), and more recent ones are targeting patients with hepatitis B (22-24). In the last few

years, Asian groups have derived and validated several HCC risk scores based on well-known risk factors such as cirrhosis, age, male sex and high HBV viral load (REACH-B, GAG-HCC, CU-HCC) (22-24). Overall, these recent scores have shown a high negative predictive value of over 95% for excluding HCC development in 3 to 10 years. These HCC risk scores were tested in several Western cohorts (25, 26), and appeared less effective in Caucasians.

In patients infected by HCV, a risk score for HCC was built whatever the stage of fibrosis (27, 28) and only one algorithm for HCC detection was developed and validated in American veterans with HCV-related cirrhosis (29), and in broader populations. While all risk scores for HCC in patients with HBV included viral load (22-24), no risk score for HCC in patients with HCV took into account a SVR.

The enhanced HCC risk assessment in our model would enable personalized screening practices. The algorithm could optimize HCC surveillance by reducing false-positives, thus having considerable impact upon subsequent testing, reducing surveillance costs and avoiding unnecessary patient/provider anxiety, while optimizing approximations of individualized patient risk. HCC risk assessments yielded by our model-based instrument can be used to create a binary decision rule for clinical action; for example, if HCC probability exceeds 20% at 5 years, then additional testing (e.g. cross-sectional imaging) could be performed. In contrast, in a very select group of patients (around 15%) with very low HCC risk (score  $\leq 3$ , 5 years; HCC cumulative incidence around 2%), the need for HCC surveillance is questionable. However it is premature to adopt fixed cutoffs at this time.

The strengths of our study lie in the following: i) the homogeneity of patients selected using stringent criteria, particularly biopsy-proven cirrhosis; ii) its prospective design, conducted at 35 centers, with systematic periodic surveillance by liver imaging for HCC screening according to international guidelines; iii) stringent monitoring of all events during follow-up, in particular HCC; iv) internal validation of results in the split sample; and vi) the fact that SVR was taken into account. Conversely, our study had several limitations, mainly linked to the small number of patients with SVR at endpoint (39.5%), due to an inclusion period prior to introduction of second-generation DDAs in clinical practice. (30, 31). However, due to the high financial cost of these new antiviral treatments, only a

minority of patients with HCV-cirrhosis worldwide had received them, even in Western countries, mainly in Europe. In addition, this HCC score could be used in countries with limited resources. Finally, our score could be applied to SVR patients whose risk scores varied from 0 to 9, with a cumulative risk of HCC at five years ranging from 0 (for a score  $\leq 3$ ) to 30.1% (for a score  $\geq 8$ ). In addition, external validation outside of France is warranted. Interestingly, we showed that the score could be accurately updated with increasing age, but also with alterations in biochemical values and modification of viral status.

In conclusion, an HCC score constructed using 4 baseline variables (age, past excessive alcohol consumption, platelet count, GGT serum level) and SVR considered as a time-dependent covariate can accurately predict HCC occurrence at an individual level in a prospective French cohort of patients with HCV-cirrhosis. It can provide individualized estimation of HCC risk of occurrence in patients with HCV-cirrhosis whatever their viral status, and can be periodically reassessed in order to decide whether or not they should be included in a surveillance program. External validation in non-French populations is warranted.

## REFERENCES

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology* 2012;142:1264-1273 e1261.
2. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology* 2004;127:S35-50.
3. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. *Gastroenterology* 2009;136:138-148.
4. Trinchet JC, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, Guyader D, et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). *Hepatology* 2015.
5. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012;56:908-943.
6. Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology* 2005;42:1208-1236.
7. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. *Gut* 2000;47:131-136.
8. N'Kontchou G, Paries J, Htar MT, Ganne-Carrie N, Costentin L, Grando-Lemaire V, Trinchet JC, et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. *Clin Gastroenterol Hepatol* 2006;4:1062-1068.
9. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. *Ann Intern Med* 2013;158:329-337.
10. Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. *J Viral Hepat* 2011;18:e516-522.
11. Bravi F, Bosetti C, Tavani A, Bagnardi V, Gallus S, Negri E, Franceschi S, et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. *Hepatology* 2007;46:430-435.
12. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne-Carrie N, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. *J Clin Endocrinol Metab* 2011;96:2601-2608.
13. Mohanty A, Tate JP, Garcia-Tsao G. Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis. *Gastroenterology* 2016;150:430-440 e431.
14. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. *Lancet* 2005;366:1059-1062.
15. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. *Am J Gastroenterol* 1999;94:2467-2474.
16. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011;53:1020-1022.
17. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegna L, Mazzella G, Ascione A, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. *Hepatology* 2007;45:579-587.
18. Di Marco V, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, Conte E, Camma C, et al. Effects of Viral Eradication in Patients with HCV and Cirrhosis Differ With Stage of Portal Hypertension. *Gastroenterology* 2016 (*In press*).

19. Huang CF, Yeh ML, Tsai PC, Hsieh MH, Yang HL, Hsieh MY, Yang JF, et al. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. *J Hepatol* 2014;61:67-74.
20. Ganne-Carrie N, Chastang C, Chapel F, Munz C, Pateron D, Sibony M, Deny P, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. *Hepatology* 1996;23:1112-1118.
21. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, Martinez I, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. *Hepatology* 2003;37:520-527.
22. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. *Lancet Oncol* 2011;12:568-574.
23. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, But DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. *J Hepatol* 2009;50:80-88.
24. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. *J Clin Oncol* 2010;28:1660-1665.
25. Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. *J Hepatol* 2015;62:363-370.
26. Abu-Amara M, Cerocchi O, Malhi G, Sharma S, Yim C, Shah H, Wong DK, et al. The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection. *Gut* 2015.
27. Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, Tsai MC, et al. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. *Br J Cancer* 2013;109:2481-2488.
28. Lee MH, Lu SN, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, et al. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. *PLoS One* 2014;9:e94760.
29. El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. *Gastroenterology* 2014;146:1249-1255 e1241.
30. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. *Hepatology* 2013;58:98-107.
31. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *Jama* 2012;308:2584-2593.

**FIGURES LEGENDS**

**Figure 1: Flow chart for patient selection.** Among 1,671 patients consecutively enrolled between March 2006 and July 2012 in the French ANRS CO12CirVir cohort, 1,323 had HCV-cirrhosis and were HBsAg-seronegative. Secondly, 243 of them were excluded from analysis due to missing data of interest (well-known predictive factors for HCC occurrence). Finally, 1,080 patients were analyzed and randomly assigned to the training (n=720) or validation (n=360) set.

**Figure 2: Incidence of HCC according to predictive score:**

**A. In the training set (n = 720):** Three groups were selected, with HCC occurrence gradually increasing from 0% to 30.1% at 5 years, for patients with the lowest ( $\leq 3$ ) and highest ( $\geq 8$ ) HCC risk scores ( $p < 0.001$ );

**B. In the validation set (n = 360):** Three groups were selected, with HCC occurrence gradually increasing from 0% to 20.3% at 5 years, for patients with the lowest ( $\leq 3$ ) and highest ( $\geq 8$ ) HCC risk scores ( $p < 0.001$ ).

*\*Since SVR is a time-dependent variable, the total number of patients at risk seems higher than expected: patients achieving SVR during follow-up were considered before SVR and after SVR for the corresponding time.*

**Figure 3: Nomogram for individualized prediction of HCC occurrence at 1, 3 or 5 years.** A nomogram derived from the score was also built, enabling individualized prediction of HCC occurrence at 1, 3 or 5 years for each level of the score. The fit of the model was assessed by Harrell's C statistics at 0.72. Calibration was also assessed for predicted HCC risk and the observed risk and showed a good correlation ( $r=0.91$ ,  $p < 0.001$ ).

## ACKNOWLEDGMENTS

**Scientific committee**

P. Nahon (principal investigator), R. Layese and F. Roudot-Thoraval (data management), P. Bedossa, M. Bonjour, V. Bourcier, S. Dharancy, I. Durand-Zaleski, H. Fontaine, D. Guyader, A. Laurent, V. Leroy, P. Marche, D. Salmon, V. Thibault, V. Vilgrain, J. Zucman-Rossi, C. Cagnot (ANRS), V. Petrov-Sanchez (ANRS).

**Clinical centers (ward / participating physicians)**

CHU Jean Verdier, Bondy (P. Nahon, V. Bourcier); CHU Cochin, Paris (S. Pol, H. Fontaine); CHU Pitié-Salpêtrière, Paris (Y. Benhamou); CHU Saint-Antoine, Paris (L. Serfaty); CHU Avicenne, Bobigny (D. Roulot); CHU Beaujon, Clichy (P. Marcellin); CHU Henri Mondor (A. Mallat); CHU Paul Brousse (P. Attali); CHU Tenon, Paris (J.D. Grangé); CHRU Hôpital Nord, Amiens (D. Capron); CHU Angers (P. Calès); Hôpital Saint-Joseph, Marseille (M. Bourlière); CHU Brabois, Nancy (J.P. Bronowicki); Hôpital Archet, Nice (A. Tran); Institut Mutualiste Montsouris, Paris (F. Mal, C. Christidis); CHU Poitiers (C. Silvain); CHU Pontchaillou, Rennes (D. Guyader); CH Pays d'Aix, Aix-en-Provence (C. Wartelle); CHU Jean Minjoz, Besançon (V. Di Martino); CHU Bordeaux - Hôpital Haut-Leveque, Pessac (V. de Ledinghen); CHU Bordeaux - Hôpital Saint-André, Bordeaux (J.F. Blanc); CHU Hôtel Dieu, Lyon (C. Trepo, F. Zoulim); CHU Clermont-Ferrand (A. Abergel); Hôpital Foch, Suresnes (S. Hillaire); CHU Caen (T. Dao); CHU Lille (P. Mathurin); CH Le Mans (C. Pilette); CHU Michallon, Grenoble (J.P. Zarski); CHU St Eloi, Montpellier (D. Larrey); CHU Reims (B. Bernard-Chabert); CHU Rouen (O. Gorja, G. Riachi); Institut Arnaud Tzanck, St Laurent-du-Var (D. Ouzan); CHU Purpan, Toulouse (J.M. Péron, L. Alric); CHU Tours (Y. Bacq).

**Funding/Support:** This study was sponsored by the ANRS (France REcherche Nord & sud Sida-hiv Hépatites: FRENH).

**Author contributions:** Professors Ganne-Carrié and Roudot-Thoraval had full access to all data in the study and take responsibility for the integrity of data and the accuracy of data analysis. Dr Nahon has listed everyone who contributed significantly to this work.

**Study concept and design:** Ganne-Carrié, Nahon, Bourcier, Roudot-Thoraval.

**Acquisition of data:** Ganne-Carrié, Bourcier, Layese, Marcellin, Guyader, Pol, Larrey, De Lédighen, Ouzan, Zoulim, Roulot, Tran, Bronowicki, Zarski, Riachi, Calès, Péron, Alric, Bourlière, Mathurin, Blanc, Abergel, Serfaty, Mallat, Grangé, Attali, Bacq, Wartelle, Dao, Benhamou, Pilette, Silvain, Christidis, Capron, Bernard-Chabert, Zucman, Di Martino, Nahon, Roudot-Thoraval.

**Analysis and interpretation of data:** Ganne-Carrié, Bourcier, Layese, Nahon, Roudot-Thoraval.

**Drafting of the manuscript:** Ganne-Carrié, Bourcier, Layese, Nahon Roudot-Thoraval.

**Critical revision of the manuscript for important intellectual content:** Ganne-Carrié, Bourcier, Layese, Nahon, Roudot-Thoraval.

**Statistical analysis:** Layese, Roudot-Thoraval

**Obtained funding:** Jean-Claude Trinchet

**Administrative, technical and material support:** Nahon, Bourcier, Cagnot, Layese, Roudot-Thoraval.

**Study supervision:** Ganne-Carrié, Bourcier, Layese, Nahon, Roudot-Thoraval

**Declaration of interests:** Prof. Ganne-Carrié and Dr. Nahon received honoraria from Bayer, Bristol-Myers Squibb, and Gilead. Prof. Zarski consults for and is on the speakers' bureau of Gilead, Bristol-Myers Squibb, Janssen, Siemens and MSD. He consults for AbbVie. Prof. Pol was a speaker for GSK, BMS, Boehringer Ingelheim, Janssen Gilead, Roche, MSD, Sanofi, Novartis, Vertex and Abbvie. He received grants from Bristol-Myers Squibb, Gilead, Roche, and MSD. He consults for Gilead, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, Vertex, Janssen, AbbVie, Sanofi, Novartis and GlaxoSmithKline. Prof. Alric consults for and received grants from Bristol-Myers Squibb, MSD, and Gilead. He received grants from Roche and Janssen. Dr. Bourlière consults for and advises AbbVie, MSD, Janssen, Bristol-Myers Squibb, Roche and Gilead. Prof. Di Martino consults for and advises Gilead, MSD, Janssen and Bristol-Myers Squibb. Dr. Bacq has served as a speaker for Roche, Gilead or Bristol-Myers Squibb. Dr. Roudot-Thoraval is an advisor for Roche, Gilead and AbbVie, and served as speaker for Roche, Bristol-Myers Squibb, AbbVie, Gilead.

**Role of the sponsor:** The funding sponsor had no role in the design or conducting of the study; collection, management, analysis, interpretation of data, nor preparation, review or approval of the manuscript.